Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
Open Access
- 1 May 2004
- journal article
- review article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 75 (5) , 677-685
- https://doi.org/10.1136/jnnp.2003.029074
Abstract
Background: Six cholinesterase inhibitors (ChEIs) have been tested in people with Alzheimer’s disease, using methods currently required for regulatory approval. The clinical importance of their treatment effects is controversial. Objective: To determine whether cholinesterase inhibition produces treatment effects in Alzheimer’s disease that are large enough to be clinically detectable. Methods: Overview analysis of published trials of ChEIs in which the Alzheimer’s Disease Assessment Scale—Cognitive Subscale (ADAS-Cog) and a global clinical measure were primary outcomes. Two quantitative summary measures of the treatment effect (Cohen’s d and the standardised response mean (SRM)) were calculated and presented as funnel plots. Observed cases analyses and intention to treat (ITT) with the last observation carried forward (LOCF) analyses were compared. Results: The median Cohen’s d effect sizes (ES) using ITT samples with LOCF for the ADAS-Cog were: low dose of a ChEI (n = 8 studies) median ES = 0.15, range = 0.03–0.22; medium dose (n = 13) median ES = 0.23, range = 0.12–0.29; high dose (n = 9) median ES = 0.28, range = 0.01–0.31. In general, the ES were larger when calculated as SRMs (for example, high dose ChEI studies, median SRM = 0.47; range = 0.30–0.63) and highest in the observed cases analyses (for example, high dose median SRM = 0.56, range = 0.35–0.78). Global clinical scales produced similar estimates of ES (for example, high dose ChEI, ITT/LOCF median Cohen’s d = 0.29, range = 0.20–0.47). Conclusions: ChEIs produce small-moderate effect sizes in clinical trials which are reproducible and demonstrate a dose response. Better descriptions of the patterns of treatment response are needed to guide individual patient decisions about the effectiveness of treatment, but group effects are evident and appear large enough to be clinically detectable.Keywords
This publication has 61 references indexed in Scilit:
- Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 RegistryAmerican Heart Journal, 2003
- Goal setting and attainment in Alzheimer's disease patients treated with donepezilJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendationsInternational Journal of Geriatric Psychiatry, 2002
- Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trialJournal of Neurology, Neurosurgery & Psychiatry, 2001
- A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo biloba Extract EGb 761® in DementiaDementia and Geriatric Cognitive Disorders, 2000
- Treatment of Alzheimer's DiseaseNew England Journal of Medicine, 1999
- Key Methodological Features of Randomized Controlled Trials of Alzheimer’s Disease TherapyDementia and Geriatric Cognitive Disorders, 1999
- The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled TrialDementia and Geriatric Cognitive Disorders, 1996
- Double-Blind, Placebo-Controlled Study of Metrifonate, an Acetylcholinesterase Inhibitor, for Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 1996
- “Mini-mental state”Journal of Psychiatric Research, 1975